ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

Headache and Migraine

Migraine Prevention: Promising New Drug

Peter Goadsby, MD discusses the efficacy, safety, & tolerability of the CGRP inhibitor erenumab in a phase III trial of participants with episodic migraine.

 

 

Headache and Migraine

This large population subset can potentially benefit from therapies that are more directly targeted to hormonally-influenced migraine headaches.

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

For several decades, studies have suggested a role for CGRP in migraine, and that targeting the CGRP pathway might help to prevent migraine.

Researchers examined two possible risk factors for migraine that potentially can be modified – having obesity and being underweight.

Research includes impact of body weight on migraine risk, effect of sleep on MS relapse, and side effects of statins in stroke survivors.

From the first hand-held vagus nerve stimulator for episodic cluster headache to a TMS therapy system for depression, we highlight 5 new technologies.

Peter Goadsby, MD discusses the efficacy, safety, & tolerability of the CGRP inhibitor erenumab in a phase III trial of participants with episodic migraine.

Pages

Subscribe to Headache and Migraine on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.